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Incidence of macrolide–
lincosamide–streptogramin B resistance 
amongst beta‑haemolytic streptococci  
in The Gambia
Ebenezer Foster‑Nyarko1, Brenda Kwambana1, Fatima Ceesay1, Kaddijatou Jawneh1, Saffiatou Darboe2, 
Sarah N. Mulwa1, Buntung Ceesay2, Ousman O. Secka2, Ifedayo Adetifa3,4 and Martin Antonio1,5,6*
Abstract 
Background: In West Africa, penicillin, macrolide and lincosamide resistance among beta‑haemolytic streptococci 
(BHS) isolates has rarely been described. However, such data are critical to detect and track the emergence of antibi‑
otic resistance.
Methods: Beta‑haemolytic streptococci were cultured from clinical specimens from patients attending the clinic at 
the Medical Research Council Unit The Gambia (n = 217) and kept at −70 °C. Of these, 186 were revived and tested 
for penicillin susceptibility by disc diffusion and E‑test methods, and the D‑test for determination of constitutive and 
inducible macrolide–lincosamide (MLSB) resistance phenotypes.
Results: The majority of BHS isolates from infections were group A streptococci (GAS) (126/186, 67.7%). Of these, 16% 
were from invasive disease (30/186). Other BHS isolated included lancefield groups B (19, 10.2%); C (9/186, 4.8%), D 
(3/186, 1.6%), F (5/186, 2.7%), G (16/186, 8.6%) and non‑typeable (8/186, 4.3%). Prevalence of BHS isolated from blood 
cultures ranges from 0% (2005) to 0.5% (2010). Most (85, 45.7%) of the isolates were from wound infections. Of the 186 
BHS isolates, none was resistant to penicillin and 14 (6.1%) were resistant to erythromycin. Of these, 8 (4.3%) demon‑
strated constitutive MLSB resistance, and 5 (2.7%) were inducible MLSB resistant. All the inducible MLSB isolates were 
GAS, and majority of the constitutive MLSB isolates (6/8, 75.0%) were non‑GAS.
Conclusions: Beta‑haemolytic streptococci, predominantly GAS are associated with a wide range of infections in 
The Gambia. It is reassuring that macrolide and lincosamide resistance is relatively low. However, monitoring of MLSB 
resistance is necessary with the global spread of resistant BHS strains.
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Background
The WHO’s global surveillance of antibiotics in 2014 
raised concerns that the management of even mild infec-
tions in both the community and hospitals is under seri-
ous threat as a result of antibiotic resistance [1, 2]. This 
marks the beginning of what has been described as a 
post-antibiotic era. Groups A–G Beta haemolytic strep-
tococci (GAS, GBS, GCS, GDS, GFS and GGS) have been 
reported to be amongst the top 10 causes of invasive bac-
terial diseases in adults and infants globally [3–5]. Whilst 
streptococci groups C–G have not previously been con-
sidered as important as GBS and GAS, emerging evi-
dence suggests that non-GAS, non-GBS (NABS) invasive 
disease is increasing [6, 7].
Penicillin is the recommended first line of treatment 
for streptococcal infections particularly that of GAS and 
GBS; however macrolides and sometimes lincosamides 
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are recommended as second line options for patients who 
are allergic to penicillin. Similar to other Gram-positive 
organisms, macrolide and lincosamide resistance have 
been reported to be emerging amongst beta- haemolytic 
streptococcal isolates globally; including reports from 
Southern Africa [8–12]. This highlights the need to probe 
resistance patterns to these antibiotic groups.
The occurrence of an erythromycin resistant, clin-
damycin susceptible isolate indicates the possibility of 
inducible clindamycin resistance, a phenomenon known 
as macrolide–lincosamide–streptogramin B (MLSB) 
resistance. For such strains, although clindamycin 
appears to be susceptible in  vitro, treatment failure is 
likely to occur, and thus it is imperative to screen for 
Macrolide–lincosamide cross-resistance (D-test) [13]. A 
positive D-test in such cases indicates cross-resistance to 
clindamycin. In West Africa, macrolide and lincosamide 
resistance amongst clinical BHS isolates have rarely been 
described. However, such data are critical to detect and 
track the emergence of antibiotic resistance. Therefore, 
we retrospectively investigated isolates of beta-haemo-
lytic streptococci recovered from patients who were seen 
at the Medical Research Council Unit The Gambia’s clinic 
in Fajara between 2004 and 2012. This study reports the 
phenotypic patterns of macrolide–lincosamide-strepto-
gramin B resistance in these pathogens.
Methods
Study area and population
Beta-haemolytic streptococci were isolated from clinical 
specimens (blood, aspirates, cerebrospinal fluid (CSF), 
throat swabs, wound swabs, urine and other miscellane-
ous specimens) collected from patients of all ages who 
attended the Medical Research Council Unit The Gam-
bia (MRCG) Clinic in Fajara, from 2004 to 2012. Iso-
lates were defined as invasive if they were isolated from 
blood, CSF or aspirates. The Clinical services department 
(CSD) of the MRCG has a 42 bed capacity. About 50,000 
patients pass through the facilities (ward, out-patient 
department, gate clinic) every year. The MRCG Clinic 
facility has been described previously [14, 15].
All beta-haemolytic streptococci were stored at −70 °C. 
Table 1 summarizes the information on the isolates used 
in this study.
The Joint Gambia Government and MRCG Ethics 
Committee approved the study.
Microbiological methods
The isolation of BHS from clinical specimen was carried 
out on 5% sheep Blood agar plates supplemented with 
gentamicin using standard microbiology techniques as 
described previously [16]. Isolates were retrieved, plated 
out on 5% sheep blood agar plates and confirmed by 
using the Streptex® Streptococcal grouping kit (Remel 
& Oxoid, Thermo Fisher Scientific, Basingstoke, UK) as 
Lancefield groups A, B, C, D, F and G.
All isolates were tested for their susceptibility to 
Penicillin discs (10 units) (BD Oxoid, Basingstoke, 
United Kingdom) using the Kirby-Bauer method. 
Table 1 Baseline Characteristics of Beta-haemolytic strep-
tococci isolates
a 75 isolates, although tested for antibiotic susceptibility, had missing records 
for sex and were thus excluded from the table
b Other comprised 18 subjects, for whom age was recorded in source document 
as child (3/18) or adult (15/18)
c Others comprised high vaginal swabs, nasal swabs, oral swabs, serum, skin 
swabs, sputum, eye swabs
n (%)
Sex
 Female 55 (49.5%)
 Male 56 (50.5%)
 Totala 111 (100%)
Age
 Less than 3 months 5 (5.1%)
 3 months to <5 years 32 (32.7%)
 5 to <15 years 12 (12.24%)
 15 to <35 years 16 (16.3%)
 35+ years 15 (15.3%)
 Otherb 18 (18.4%)
 Total 98 (100%)
Year isolated
 2004 4 (2.2%)
 2005 1 (0.5%)
 2006 7 (3.8%)
 2007 29 (15.6%)
 2008 38 (20.4%)
 2009 51 (27.4%)
 2010 24 (12.9%)
 2011 21 (11.3%)
 2012 11 (5.9%)
 Total 186 (100%)
Source of isolation
 Blood culture 21 (11.3%)
 Ear swab 34 (18.3%)
 Aspirates 8 (4.3%)
 Throat swab 15 (8.1%)
 Wound swab 85 (45.7%)
 CSF 1 (0.5%)
 Urine 9 (4.8%)
 Othersc 13 (7.0%)
 Total 186 (100%)
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Mueller–Hinton agar supplemented with 5% sheep blood 
(MHA) was used for the susceptibility testing. All isolates 
showing resistance or intermediate sensitivities to peni-
cillin were subjected to the E-test. All the BHS isolates 
were further screened by the D-test method using 15 µg 
Erythromycin and 2 µg Clindamycin discs to determine 
macrolide–lincosamide-streptogramin resistance follow-
ing Clinical and Laboratory Standards Institute (CLSI) 
guidelines [13].
All interpretation of antibiotic susceptibilities were 
done using CLSI breakpoints [13]. All reagents and the 
disc dispenser were obtained from BD Oxoid, Basing-
stoke, UK, except for E-test strips which were obtained 
from Biomerieux, UK Limited. The MRCG submits to 
the external quality assurance programme of the UK 
National External Quality Assessment Service [17] and is 
a World Health Organization (WHO) Regional Reference 
Laboratory for invasive bacterial diseases (IBD).
Data management
Patient information and BHS culture data were collected 
from MRCG clinic’s microbiology records. The total 
number of blood and CSF cultures performed per year 
over the study period was similarly collected from the 
clinical microbiology records. From the clinic data, age 
was recorded as a continuous variable but was conveni-
ently categorized into 5 groups. All these variables were 
summarized using frequency counts and percentages, n 
(%). Associations between baseline variables age and gen-
der as well as responses to the 3 antibiotics with group 
were explored using Fishers exact tests.
Results
This study retrospectively analyzed clinical isolates of 
BHS derived from patients who attended the MRCG’s 
clinic from 2004 to 2012. Of 217 isolates collected over 
the study period, 186 (85.7%) were successfully revived 
for further testing. Only one isolate per patient was 
included in the study.
Table 1 summarizes the characteristics of the patients 
from whom BHS were isolated. Laboratory records clini-
cal isolates were mostly sparse for 2004 and 2005; and 
for some years not all clinical information was available. 
Of the patients who had complete clinical records, there 
were approximately equal numbers of males and females. 
Most (32, 26.1%) of the samples came from 3 months to 
5 year olds; and from wound infections (32, 26.1%). The 
overall distribution of lancefield groups A-G is as follows: 
Group A dominated (126, 67.8%); followed by GBS (19, 
10.2%); GGS (16, 8.6%); GCS (9, 4.8%); NT (8, 4.3%) GFS 
(5, 2.7%) and GDS (3, 1.6%). Approximately 16% of these 
isolates were from invasive disease (30/186) i.e. aspirates, 
blood cultures and CSF (Table 1). These comprised GAS 
(19/30, 63.3%); NT (3/30; 10%); GBS (2/30; 6.7%); GCS 
(2/30; 6.7%); GDS; 2/30; 6.7%) and GFS (2/30; 6.7%). The 
majority of BHS isolates were from wound infections.
Of the major BHS groups (GAS, GBS and GGS), the 
proportions of isolates amongst males and females dif-
fered significantly (p = 0.03), with GAS having the high-
est proportion (84/100; 84%) (Table 3).
Of 30 isolates recovered from sterile sites, 9 (30%) were 
of BHS groups C-G; namely 2 GFS, 2 GDS, 2 GCS and 3 
were non-typeable BHS.
Of the 186 BHS isolates, 13 (6.9%) across all lancefield 
groups were resistant to penicillin by the disc diffusion 
method; however E-test resolved all of these as sensi-
tive (100%). Overall, 14 out of the 186 isolates (6.1%) 
were resistant to erythromycin. The phenotypic profiles 
of macrolide–lincosamide resistance of the erythromy-
cin resistant isolates are presented in Table 2. Notably, all 
isolates that were iMLSB isolates belonged to lancefield 
group A. However, all 3 isolates that exhibited clindamy-
cin resistance only were non-GAS (1 GDS, 1GBS and 1 
GCS). Similarly, as can be seen from Table 2, 6 out of 8 
(75%) of the cMLSB isolates that were found in this study 
were non-GAS (1 GDS, 3GDS, and 2 GBS).
The resistance of isolates to erythromycin did not 
appear to differ across BHS groups (p =  0.4) (Table  3). 
That of clindamycin showed some borderline difference 
between the BHS groups (p = 0.04); with the greater pro-
portion of GAS being sensitive to this antibiotic. Penicil-
lin resistance however did not differ amongst GAS, GBS 
and GGS (p = 0.3).
Discussion
Here we have given the first report of erythromycin 
resistance and macrolide–lincosamide–streptogramin 
cross-resistance in beta-haemolytic streptococci from 
West Africa. We find an overall erythromycin resistance 
of 6.1% amongst clinical isolates in The Gambia, and no 
penicillin resistance amongst beta-haemolytic strepto-
cocci isolates in our study population.
These findings are similar to what has been reported 
from other middle to low income settings. In a Turkish 
Table 2 Phenotypic resistance patterns amongst  clinical 
BHS isolates (n = 186)
MLSB Macrolide–lincosamide–streptogramin B resistance phenotype
n (%)
Inducible MLSB 5 (2.7%)
Constitutive MLSB 8 (4.3%)
Macrolide resistance only 2 (1.1%)
Clindamycin resistance only 3 (1.6%)
Macrolide–lincosamide susceptible 168 (90.3%)
Total 186 (100%)
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study, 9% of clinical GAS isolates were found to be resist-
ant to erythromycin; and all of them were inducibly 
resistant to clindamycin [10]. In India, 12% of groups C 
and G isolates from carriage and clinical sources com-
bined were reported to be erythromycin resistant [11].
Contrary to what we found, rates of erythromycin 
resistance of up to 44% have been reported amongst 
clinical GBS isolates from Taiwan [8]. A Korean study of 
macrolide resistance amongst BHS isolates from a ter-
tiary hospital also reported a high rate of 37% resistance 
of GBS to erythromycin, but a reduced rate of 5% resist-
ance of GAS to erythromycin, and no clindamycin resist-
ance [18]. In that study, GCS and GGS isolates recorded 
erythromycin resistance of 9.4 and 3.1% respectively.
Comparison of these and published figures suggest 
that erythromycin and clindamycin resistance varies 
greatly between different geographical areas; notably in 
line with differing selective pressure from antibiotic use, 
along with other factors [19, 20]. Widespread use of anti-
biotics and intrapartum prophylaxis are contributing to 
the emergence of macrolide resistance [19, 21]. Antibi-
otic use drives the selection pressure that results in the 
emergence of resistance; however this has been linked 
with high consumptions beyond a critical theoretic 
threshold [19, 20]. In The Gambia, similar to other West 
African countries, intrapartum prophylaxis is not prac-
ticed. Clindamycin use is restricted, although since 2013 
erythromycin is routinely used to treat infections of the 
skin and lower respiratory tract [22]. Resistance amongst 
BHS to clindamycin and erythromycin has not been 
reported prior to this study. Moreover, access to antibiot-
ics in the Gambia is relatively limited due to reasons of 
cost. These may account for the low level of clindamycin 
and erythromycin resistance that we found amongst our 
isolates in this study. The annual patient population at 
MRCG clinic is about 2.5% of the Gambian population 
(~1.9 million).
Similar to our findings, no resistance to erythromy-
cin and clarithromycin were found amongst 64 Gam-
bian H. pylori strains isolated from gastric biopsies [22]. 
We previously reported the prevalence of erythromycin 
resistance amongst 162 carriage isolates of GBS to be 
3.1% [23]. In another study involving 151 Staphylococcus 
aureus isolates, no resistance to erythromycin was found, 
and the highest resistance rate was 34% of overall iso-
lates; to tetracycline [24]. Similarly high levels of suscep-
tibilities to a wide range of antibiotics have been reported 
amongst invasive strains of Streptococcus pneumoniae 
and Salmonella from the Gambia [14, 25].
Of note, all the iMLSB isolates that were found in this 
study were GAS. However, all 3 isolates that exhib-
ited clindamycin resistance only were non-GAS (1 
GDS, 1GBS and 1 GCS). Similarly, 6 out of 8 (75%) of 
the cMLSB isolates that were found in this study were 
Table 3 Epidemiology and antibiotic resistance rates amongst the predominant BHS groups
a Other comprised 18 subjects, for whom age was recorded in source document as child (3/18) or adult (15/18)
Characteristic Category GAS GBS GGS Total p value
Sex, n (%) Female 47 (88.7) 2 (3.8) 4 (7.5) 53 (100.0) 0.03
Male 37 (78.7) 9 (19.2) 1 (2.1) 47 (100.0)
Total 84 (84.0) 11 (11.0) 5 (5.0) 100 (100.0)
Age, n (%) ≤3 month 4 (80.0) 1 (20.0) 0 (0.00) 5 (100.0) 0.03
3 month to ≤5 years 26 (100) 0 (0.0) 0 (0.0) 26 (100.0)
5 to  ≤15 years 12 (100.0) 0 (0.0) 0 (0.0) 12 (100.0)
15–35 years 11 (68.8) 3 (18.8) 2 (12.5) 16 (100.0)
>35 years 9 (69.2) 3 (23.08) 1 (7.69) 13 (100.0)
Othersa 12 (70.6) 3 (17.7) 2 (11.8) 17 (100.0)
Total 74 (83.2) 10 (11.2) 5 (5.6) 89 (100.0)
Penicillin resistance, n (%) Resistant 5 (71.4) 2 (28.6) 0 (0.0) 7 (100.0) 0.3
Sensitive 121 (78.57) 17 (11.0) 16 (10.4) 154 (100.0)
Total 126 (78.3) 19 (11.8) 16 (9.9) 161 (100.0)
Clindamycin resistance, n (%) Intermediate 1 (100.0) 0 (0.0) 0 (0.0) 1 (100.0) 0.04
Resistant 2 (33.3) 3 (50.0) 1 (16.7) 6 (100.0)
Sensitive 123 (79.9) 16 (10.4) 15 (9.7) 154 (100.0)
Total 126 (78.3) 19 (11.8) 16 (9.9) 161 (100.0)
Erythromycin resistance, n (%) Intermediate 6 (66.7) 2 (22.2) 1 (1.1) 9 (100.0) 0.4
Resistance 8 (66.7) 2 (16.7) 2 (16.7 12 (100.0)
Sensitive 112 (80.0) 15 (10.7) 13 (9.3) 140 (100.0)
Total 126 (78.3) 19 (11.8) 16 (9.9) 161 (100.0)
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non-GAS (1 GDS, 3GDS, and 2 GBS). Although erythro-
mycin resistance across the three dominant BHS groups 
(GAS, GBS and GGS) did not differ significantly, we 
observed some difference between the sensitivity of clin-
damycin across the BHS groups. Our findings suggest 
that BHS antibiotic resistance, particularly due to NABS 
may be under-reported in West Africa.
The prevalence of BHS isolated from blood ranged 
from 0% (2005) to 0.5% (2010). Of 30 isolates recov-
ered from sterile site, 9 (30%) were of BHS groups C-G; 
namely 2 GFS, 2 GDS, 2 GCS and 3 were non-typeable 
BHS. Although the proportions found were quite small, 
our study shows that this group of bacteria may consti-
tute neglected disease. In the US, an active population 
and laboratory-based surveillance found 489 invasive 
NABS from hospitalized patients over a 2  year period 
[6]. Mortality rates of 3–10% due to NABS have been 
reported from Australia [7].
There are several limitations to the design and labora-
tory methods used in this study that limit its application 
to similar settings. First, the clinical isolates were cho-
sen from patients who visited the MRCG clinic at Fajara 
during the study period; thus the prevalence of mac-
rolide resistance we found may not be representative of 
the entire Gambian population. Furthermore, for some 
clinical isolates, some clinical information were missing 
from the laboratory records. Despite these limitations, 
this study provides important baseline information on 
the patterns of macrolide and lincosamide resistance 
amongst clinical isolates of BHS in the Gambia. Our 
findings indicate that monitoring of macrolide–lin-
cosamide cross-resistance is warranted; and support 
the routine screening of in clinical isolates before treat-
ment. It would be desirable for future studies to inves-
tigate the genotypes of resistance, and correlate these 
with the resistance that has been reported here.
Conclusions
Beta-haemolytic streptococci, predominantly GAS are 
associated with a wide range of infections in The Gambia. 
It is reassuring that macrolide and lincosamide resistance 
is relatively low. However, monitoring of MLSB resistance 
is necessary with the global spread of resistant BHS strains.
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